{"nctId":"NCT03260894","briefTitle":"Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)","startDateStruct":{"date":"2017-12-07","type":"ACTUAL"},"conditions":["Renal Cell Carcinoma (RCC)"],"count":129,"armGroups":[{"label":"Pembrolizumab + Epacadostat","type":"EXPERIMENTAL","interventionNames":["Drug: Pembrolizumab","Drug: Epacadostat"]},{"label":"SoC (Sunitinib or Pazopanib)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Sunitinib","Drug: Pazopanib"]}],"interventions":[{"name":"Pembrolizumab","otherNames":["MK-3475"]},{"name":"Epacadostat","otherNames":["INCB024360"]},{"name":"Sunitinib","otherNames":["Sutent","SU11248"]},{"name":"Pazopanib","otherNames":["Votrient"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologic confirmation of locally advanced or metastatic RCC with a clear-cell component with or without sarcomatoid features.\n* Must not have received any prior systemic therapy for their mRCC.\n* Measurable disease based on RECIST v1.1.\n* Archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion as required.\n* Karnofsky performance status â‰¥ 70%.\n* Adequate organ function per protocol-defined criteria.\n\nExclusion Criteria:\n\n* Use of protocol-defined prior/concomitant therapy.\n* Currently receiving or has received an investigational treatment as part of a study of an investigational agent or has used an investigational device within 4 weeks before randomization.\n* History of severe hypersensitivity reaction to study treatments or their excipients.\n* Active autoimmune disease that has required systemic treatment in past 2 years.\n* Known additional malignancy that has progressed or has required active treatment in the last 3 years.\n* Known active central nervous system metastases and/or carcinomatous meningitis.\n* History of (noninfectious) pneumonitis that required steroids or current pneumonitis.\n* History or presence of an abnormal electrocardiogram that, in the investigator's opinion, is clinically meaningful.\n* Significant cardiac event within 12 months before Cycle 1 Day 1.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Objective Response Rate (ORR) of Pembrolizumab + Epacadostat Versus Standard of Care (SOC)","description":"ORR was defined as the percentage of participants who had complete response (CR) or partial response (PR) per RECIST v1.1 by investigator determination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.7","spread":null},{"groupId":"OG001","value":"29.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.3","spread":null},{"groupId":"OG001","value":"29.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Safety and Tolerability of Pembrolizumab + Epacadostat Versus SOC as Measured by the Number of Participants Experiencing Adverse Events (AEs)","description":"AE is defined as any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"63","spread":null}]}]}]},{"type":"SECONDARY","title":"Safety and Tolerability of Pembrolizumab + Epacadostat Versus SOC as Measured by the Number of Participants Discontinuing Study Drug Due to AEs","description":"AE is defined as any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":18,"n":64},"commonTop":["Diarrhoea","Nausea","Hypertension","Fatigue","Anaemia"]}}}